AAAhmed M. E. Abdalla

Ahmed M. E. Abdalla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmed M. E. Abdalla has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Yu Miao

    NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital

    5 shared publications
  • Chenxi Ouyang

    Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

    4 shared publications
  • Guang Yang

    Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China

    3 shared publications
  • Chenxi Ouyang

    Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    2 shared publications
  • Lixia Huang

    Hubei Key Laboratory of Purification and Application of Plant Anti-Cancer Active Ingredients, School of Chemistry and Life Sciences, Hubei University of Education, Wuhan 430205, China

    2 shared publications
  • Ning Meng

    School of Biological Sciences and Technology, University of Jinan

    2 shared publications

Latest Publications

  • Elucidating the mechanism of ADAM10/PD-L1 interaction in pancreatic adenocarcinoma cell lines using cellular and computational analyses

    by Ahmed M. E. Abdalla, Yu Miao, Yasir A. Taha, Mohnad Abdalla, Wafa Ali Eltayb, Sami Fatehi Abdalla, Ning Meng, Chenxi Ouyang

    1. Cancer immunotherapy is a therapeutic method for fighting cancer by stimulating or generating an immune response against tumors (Taefehshokr et al., 2022). Diverse cancer immunotherapeutic metho...

  • Upregulation of ADAM10 reinforces CD8 + T cells toward exhaustion in the TME

    by Ahmed M. E. Abdalla, Yu Miao, Yasir A Taha, Ning Meng, Chenxi Ouyang

    The human genome encodes 22 distinct A disintegrin and metalloproteases (ADAMs), which are required for various developmental activities, including spermatogenesis, the central nervous system, and ...


  • Strategies of AI ‐Driven CAR ‐T Cell Therapy Towards Solid Tumours

    by Ahmed M. E. Abdalla, Yu Miao, Yasir A. Taha, Ning Meng, Chenxi Ouyang

    Chimeric antigen receptor (CAR)‐T cell immunotherapy shows significant success in hematologic malignancies. However, it faces critical challenges in solid tumours, such as suppressive tumour microenvironment (TME) and antigenic heterogeneity, highlighting the urgent need for effective and safe CAR products. The integration of artificial intelligence (AI) into CAR‐T cell immunotherapy offers exceptional opportunities to improve its therapeutic efficacy. More specifically, this paper highlights the transformative role of AI in addressing key challenges that impede the success of CAR‐T cell therapy in solid tumours, including assisting in CAR design and manufacturing process, identifying novel CAR‐targeted genes, and detecting cell heterogeneity in solid tumours. We remain optimistic about AI‐driven strategies for enhancing CAR T‐cell persistence, trafficking, and visualisation in the TME. In addition, we highlight the current challenges and prospects for advancing AI‐driven CAR‐T cell therapies.


  • ADAM10 modulates the efficacy of T‐cell‐mediated therapy in solid tumors

    by Ahmed Me Abdalla, Yu Miao, Ning Ming, Chenxi Ouyang

    T‐cell‐mediated therapeutic strategies are the most potent effectors of cancer immunotherapy. However, an essential barrier to this therapy in solid tumors is disrupting the anti‐cancer immune response, cancer‐immunity cycle, T‐cell priming, trafficking and T‐cell cytotoxic capacity. Thus, reinforcing the anti‐cancer immune response is needed to improve the effectiveness of T‐cell‐mediated therapy. Tumor‐associated protease ADAM10, endothelial cells (ECs) and cytotoxic CD8+ T cells engage in complex communication via adhesion, transmigration and chemotactic mechanisms to facilitate an anti‐cancer immune response. The precise impact of ADAM10 on the intricate mechanisms underlying these interactions remains unclear. This paper broadly explores how ADAM10, through different routes, influences the efficacy of T‐cell‐mediated therapy. ADAM10 cleaves CD8+ T‐cell‐targeting genes and impacts their expression and specificity. In addition, ADAM10 mediates the interactions of adhesion molecules with T cells and influences CD8+ T‐cell activity and trafficking. Thus, understanding the role of ADAM10 in these events may lead to innovative strategies for advancing T‐cell‐mediated therapies.


  • CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives

    by Ahmed M. E. Abdalla, Yu Miao, Ning Meng, Chenxi Ouyang

    Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advancements. However, the current models of CAR‐T cells need further improvement since the T cells are associated with the triggering of excessive inflammatory cytokines that directly affect cardiac functions. Thus, the current study highlights the critical function of heart immune cells in tissue fibrosis and repair. The study also confirms CAR‐T cell as an emerging therapeutic for treating cardiac fibrosis, explores the current roadblocks to CAR‐T cell therapy, and considers future outlooks for research development.


  • Polyethylenimine-coated gold-magnetic nanoparticles for ADAM10 siRNA delivery in prostate cancer cells

    by Raju Panday, Ahmed Me Abdalla, Yu Miao, Xiaohong Li, Manisha Neupane, Chenxi Ouyang, Guang Yang

    For an effective medical application of therapeutic siRNA, a safe and an efficient delivery system are required. Herein, magnetic nanoparticles (MNPs) have been successfully used as siRNA delivery vehicles. Firstly, MNPs were coated with gold (Au) nanoparticles and then capped with PEI. To improve the biocompatibility of nanoparticles, hyaluronic acid (HA) was coated onto the surface of PEI-Au/Fe nanoparticles. The prepared HA-PEI-Au/Fe3O4 nanoparticles were characterized and found to be uniform and well segregated in TEM analysis. FTIR analysis confirmed that HA was successfully conjugated to PEI. The polymer content in these nanoparticles was relatively higher than PEG coated nanoparticles. Cell viability assay demonstrated that the nanoparticles were relatively biocompatible in nature. ADAM10 siRNA was loaded into the HA-PEI-Au/Fe3O4 nanoparticles and cytotoxicity to prostate cancer (PC3) cells was analyzed. The results indicate that ADAM10 siRNA loaded HA-PEI-Au/Fe3O4 suppress the PC3 cells growth in vitro. Clearly, it could be confirmed that HA-PEI coated Au/Fe3O4 nanoparticles with higher biocompatibility appear to be suitable for intracellular siRNA delivery.


  • Open Access

    Biopolymer-Based Microcarriers for Three-Dimensional Cell Culture and Engineered Tissue Formation

    by Lixia Huang, Ahmed M.E. Abdalla, Lin Xiao, Guang Yang

    The concept of three-dimensional (3D) cell culture has been proposed to maintain cellular morphology and function as in vivo. Among different approaches for 3D cell culture, microcarrier technology provides a promising tool for cell adhesion, proliferation, and cellular interactions in 3D space mimicking the in vivo microenvironment. In particular, microcarriers based on biopolymers have been widely investigated because of their superior biocompatibility and biodegradability. Moreover, through bottom-up assembly, microcarriers have opened a bright door for fabricating engineered tissues, which is one of the cutting-edge topics in tissue engineering and regeneration medicine. This review takes an in-depth look into the recent advancements of microcarriers based on biopolymers—especially polysaccharides such as chitosan, chitin, cellulose, hyaluronic acid, alginate, and laminarin—for 3D cell culture and the fabrication of engineered tissues based on them. The current limitations and potential strategies were also discussed to shed some light on future directions.


  • Capacity of gold nanoparticles in cancer radiotherapy

    by Nadeem M. S. Nagi, Yasir A. M. Khair, Ahmed M. E. Abdalla

    Radiotherapy is the ionizing radiation used for treatment of cancer and other diseases. Although radiotherapy is the major treatment for cancer, a lot of patients do not undergo radiation due to associated risks such as radiation pneumonitis, cardiovascular complications, development of secondary tumor, and lymphedema. However, the advantages of nanotechnology provide a unique potential to enhance radiotherapeutic performance, in particular by utilizing gold nanoparticles (Au NPs). In this review, we briefly describe the current direction of research towards the use of Au NPs for radiotherapeutic enhancement, combination, monitoring and in side effect reductions.